Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Pikralida logo — Pikralida - A drug development company

Pikralida

Pikralida - A drug development company

Founded 2019 Poland Poland 20 employees Unknown Total: $16.70M

General Information

Company Name Pikralida
Founded Year 2019
Location Poland Poland +2
Employees 20
Funding Stage Unknown
Social

Get notified when Pikralida moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Pikralida

Pikralida, founded in 2019 and headquartered in Poland, is a dynamic biotechnology company that seamlessly integrates the development of innovative therapies with Contract Research Organization (CRO) services. Its hybrid business model offers both proprietary drug development and partnered research opportunities, positioning the company for strategic growth in the global marketplace.

The company's flagship program revolves around PKL-021 (marimastat), a potent matrix metalloprotease (MMP) inhibitor, currently advancing in clinical trials for key indications such as neuroprotection from strokes and treatments for snakebite envenoming. These initiatives underscore its commitment to addressing high-impact therapeutic areas.

Pikralida's recent PLN13.30M Early VC investment, funded by notable investors including Tanis Ventures, Altamira, Hard2beat, and iif.vc, reflects strong backing for its global ambitions. The company's integration of CRO services enhances its value proposition by offering tailored R&D solutions to the biotech and pharmaceutical industries.

Taxonomy: Contract Research Organization, Drug Development, Neuroprotection, Stroke Therapy, Snakebite Treatment, MMP Inhibitors, Pharmaceutical Research, Therapeutic Innovation, Preclinical Programs, Clinical-stage Development, Pharmaceutical Analysis, Formulation Development, Strategic Partnerships, Global Market Introduction

Services & Products

Contract Research Services
Research and Development Projects
Therapeutic Innovations

Target Customers

Pharmaceutical Companies Biotech Firms Healthcare Innovators

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC •••••• 4
Investor
•••• •••• 		01 Nov 2025
Seed •••••• 1 •••• •••• 01 Apr 2023

Pikralida Alternatives & Competitors

View All Alternatives
Pikralida vs
GESLabs
GESLabs United Kingdom

Leading Naturally

41 employees
Biotechnology, Health and Wellness
Pikralida vs
Athersys
Athersys United States

Committed to developing therapies to extend and enhance the quality of life.

Post Ipo Equity
37 employees
Biopharma, Biotechnology
Pikralida vs
TFS HealthScience
TFS HealthScience Sweden

Empowering Partners. Enriching Lives.

764 employees
View all alternatives

FAQ About Pikralida

Pikralida - A drug development company
Pikralida was founded in 2019.
Pikralida is headquartered in Poland.
Pikralida has approximately 20 employees.
Pikralida has completed 2 funding rounds, raising a total of $16.70M. The latest funding stage is Unknown.
Pikralida offers: Contract Research Services, Research and Development Projects, Therapeutic Innovations.
Top alternatives and competitors to Pikralida include GESLabs, Athersys, TFS HealthScience, GX Pharma, Advenchen Laboratories, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pikralida and GESLabs are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Pikralida and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy